Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer

7 Jul 2009

Abstract excerpt

A better understanding of drug resistance mechanisms is required to improve outcomes in patients with pancreatic cancer. Here, we characterized patterns of sensitivity and resistance to three conventional chemotherapeutic agents with divergent mechanisms of action [gemcitabine, 5-fluorouracil (5-FU), and cisplatin] in pancreatic cancer cells. Four (L3.6pl, BxPC-3, CFPAC-1, and SU86.86) were sensitive and five...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Epigenetics and DNA Methylation
Share to Pancreatic and Hepatic Oncology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19584296
DOI: 10.1158/0008-5472.can-08-2819

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic CancerPMID 19584296Read ↗

Gemcitabine‐induced epithelial‐mesenchymal transition‐like changes sustain chemoresistance of pancreatic cancer cells of mesenchymal‐like phenotypeSemantic proximity Read ↗

ZEB1 in Pancreatic CancerSemantic proximity Read ↗

Multidrug resistance genes screening of pancreatic cancer based on sensitivity profile to chemotherapeutic drugsSemantic proximity Read ↗

Overcoming drug resistance in pancreatic cancer.Semantic proximity Read ↗

Multidrug resistance genes screening of pancreatic ductal adenocarcinoma based on sensitivity profile to chemotherapeutic drugsSemantic proximity Read ↗

MicroRNAs in pancreatic cancer drug resistance: mechanisms and therapeutic potentialSemantic proximity Read ↗

Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway.Semantic proximity Read ↗

Association of the Epithelial–Mesenchymal Transition (EMT) with Cisplatin ResistanceSemantic proximity Read ↗

Identification of chemoresistance‐related mRNAs based on gemcitabine‐resistant pancreatic cancer cell linesSemantic proximity Read ↗

Sclareolide enhances gemcitabine‑induced cell death through mediating the NICD and Gli1 pathways in gemcitabine‑resistant human pancreatic cancer.Semantic proximity Read ↗

Challenges of drug resistance in the management of pancreatic cancerSemantic proximity Read ↗

The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.